All but one patient with ERBB2 amplification identified in this study had concomitant overexpression of HER2 by IHC and had received HER2-targeted therapy as standard of care (fluoropyrimidine and platinum combined with trastuzumab in all cases) prior to molecular tumour board meeting. This evidence concerns the gene ERBB2 and neoplasm.